2016 Future of Financials Conference Management and client bullishness implies further upside Price Objective Change Equity | 17 November 2016 Corrected Unauthorized redistribution of this report is prohibited. This report is intended for [email protected] Conference tone bull...
Results for “Novartis Institutes for BioMedical Research”
Search across the indexed text of every released document.
Names that match “Novartis Institutes for BioMedical Research”
1,177 documents found
European Equity Strategy 2017 year ahead – Refining the reflation rotation 01 December 2016 Unauthorized redistribution of this report is prohibited. This report is intended for [email protected] Key takeaways • 2017 - Reflation, Reversal, Rotation, Relief or Revolt. EPS to tu...
Internet/e-Commerce 1Q Internet Sector Preview Earnings Preview Equity | 06 April 2017 Unauthorized redistribution of this report is prohibited. This report is intended for [email protected] 1Q Preview; Expectations building on a strong 2H Our early sector preview highlights o...
INTELLECTUAL JAZZ DAVID AGUS DAN ARIELY KEITH BLACK DAVID BLAINE MIKE BLOCK ADAM B LY SCOTT BOLTON DAVID BROOKS MARK CUBAN ANTONIO DAMASIO JACK DANGERMOND DAVE GALLO FRANK GEHRY MATT GROENING HERBIE HANCOCK DANNY HILLIS BJARKE INGELS QUINCY JONES MARY JORDAN JON KAMEN JEFFREY KA...
Top 10 US Ideas Quarterly Q1 Top 10 Ideas Strategy Equity | 03 January 2017 Corrected Top 10 US Ideas – 1Q17 The backdrop for risk assets has changed dramatically over the past year. As Michael Hartnett pointed out, 2016 saw global interest rates fall to 5,000-year lows and the...
Global Cross Asset Strategy – Year Ahead The Trump inflection Investment Strategy 30 November 2016 Corrected Key takeaways • Market response to Trump is logical but moves have been frontloaded. We now see USD & rates only modestly higher next year. • We see higher growth and inf...
National Pub date: February 19, 2019 Title: DEEP THINKING Subtitle: Twenty-Five Ways of Looking at AI By: John Brockman Length: 90,000 words Headline: Science world luminary John Brockman assembles twenty-five of the most important scientific minds, people who have been thinking...
…NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Scien...
Liquid Insight Trump’s effect on MXN 22 September 2016 Unauthorized redistribution of this report is prohibited. This report is intended for [email protected] Key takeaways • We provide an empirical analysis of Donald Trump's potential effects on the Mexican peso • Our analysi...
Japan Macro Watch USD/JPY: Buy-on-dip cycle to continue; 115- 120 by end-2017 14 November 2016 Buy-on-dip cycle continues While we had acknowledged the risk of the “final JPY strength” this autumn on the BoJ's limit and US elections, it has been our view that the USD/JPY’s dips...
The Seventh Sense Power, Fortune and Survival in the Age of Networks Joshua Cooper Ramo 1 . Part One: The Nature of Our Age In which the revolutionary character of our era is explained. The need for a new instinct is introduced. The historical stakes are weighed. Chapter 1: The...
PRAISE FOR The 4-Hour Workweek “It’s about time this book was written. It is a long-overdue manifesto for the mobile lifestyle, and Tim Ferriss is the ideal ambassador. This will be huge.” —JACK CANFIELD, cocreator of Chicken Soup for the Soul®, 100+ million copies sold “Stunnin...
COWEN COLLABORATIVE INSIGHTS February 25, 2019 ADDENDUM Stocks Mentioned In Important Disclosures Ticker Company Name WEED Canopy Growth Corporation GWPH GW Pharmaceuticals Plc TLRY Tilray TPB Turning Point Brands Important Disclosures and Information Relating to Cowen Wash...
COWEN COLLABORATIVE INSIGHTS February 25, 2019 Equity Research Price Targets: Cowen and Company, LLC assigns price targets on all companies covered in equity research unless noted otherwise. The equity research price target for an issuer's stock represents the value that the ana...
…d ongoing contracts and right of first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. • Grew research revenue by increasing clinical trials by 40% and...